SKLB-329

SKLB-329 is a novel, orally administered multikinase inhibitor developed for the treatment of hepatocellular carcinoma. It inhibits angiogenesis-related kinases including VEGFR1, VEGFR2, VEGFR3, FGFR2, and the tyrosine-protein kinase Src. SKLB-329 acts by inhibiting endothelial cell growth, migration, invasion, and tube formation, demonstrating potent anti-angiogenic activity and inhibiting tumor cell proliferation through down-regulation of Src-mediated FAK and Stat3 signaling pathways. It has shown significant anti-tumor activity in preclinical models, with favorable pharmacokinetic properties and higher potency than sorafenib in some assays[1][2][3][5][9].